Saturday 17 October 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.
19.81
1.53
−7.17%
Follow FLGT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.77 | 1.53 | 2.51 | 2.20 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(24.19) | 69.19 | (10.35) | 62.57 | |
P/B ratio |
0.58 | 0.47 | 0.73 | 0.62 | |
Price to Tangible BV |
0.67 | 0.54 | 0.80 | 0.72 | |
EV/Sales |
1.05 | 0.74 | 1.53 | 1.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.05) | (2.62) | (4.85) | 223.29 | |
EV/FCF |
(3.26) | (2.08) | (3.97) | (17.14) | |
Quick Ratio |
4.49 | 3.83 | 4.95 | 6.17 | |
Current Ratio |
6.34 | 5.31 | 6.48 | 7.01 | |
Net Debt/EBITDA |
8.82 | 9.36 | 8.20 | 778.06 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.27 | 0.27 | 0.26 | |
Operating CF/Net income |
0.80 | (0.29) | 3.34 | (1.68) | |
Capex/Depreciation |
(0.56) | (1.02) | 1.05 | (0.41) | |
Interest Coverage |
(611.41) | (2,036.59) | (2,264.87) | (548.21) | |
Research and Development Expense of Revenue |
17.04% | 19.93% | 17.00% | 16.49% | |
Selling, General and Administrative Expense of Revenue |
49.68% | 56.10% | 63.15% | 41.61% | |
Intangible Assets out of Total Assets |
0.12 | 0.12 | 0.07 | 0.13 | |
Share Based Compensation of Revenue |
10.10% | 13.90% | 11.13% | 11.56% | |
Graham Net Nets |
0.63 | 0.75 | 0.55 | 0.60 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.74%) | (15.03%) | (7.46%) | (6.15%) | |
Free Cash Flow Yield |
(18.06%) | (23.05%) | (15.36%) | (2.86%) | |
Revenue per Share |
3.05 | 2.30 | 2.71 | 2.73 | |
Operating CF per Share |
(0.85) | 0.23 | (2.54) | 0.36 | |
Capex per Share |
(0.14) | (0.17) | (0.16) | (0.20) | |
Free Cash Flow per Share |
(0.99) | 0.06 | (2.70) | 0.16 | |
Cash per Share |
9.18 | 8.95 | 10.92 | 12.22 | |
Shareholders Equity per Share |
35.56 | 33.81 | 35.96 | 36.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
35.56 | 33.81 | 35.96 | 36.45 | |
Free Cash Flow |
(27.62) | 1.90 | (83.12) | 5.06 | |
Working Capital |
383.01 | 388.91 | 465.52 | 434.95 | |
Capital Expenditures |
(3.86) | (5.19) | (4.98) | (6.05) | |
Net Current Asset Value |
361.53 | 366.83 | 443.68 | 413.57 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.07 | 0.06 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
71.06 | 70.38 | 76.89 | 64.25 | |
Average Payables |
17.22 | 19.68 | 18.51 | 18.95 | |
Average Assets |
1,144.53 | 1,181.06 | 1,216.74 | 1,224.16 | |
Average Common Equity |
1,053.81 | 1,083.46 | 1,117.94 | 1,127.83 |
Columns are period end dates